
Emergency Diagnosis of Lung Cancer: A European Problem

Dr Tom Newsom-Davis


Consultant Medical Oncologist


Chelsea & Westminster Hospital, London

EUROCARE-5: Lung Cancer




Excess Lung Cancer Deaths






Lung Cancer Survival by Route


Relative survival estimates by presentation route and survival time, Lung, 2006-2008, aged 65-84



Causes of Emergency Presentation



European Thoracic Oncology Members



Rates of Emergency Diagnosis


Country	Total Patients		Emergency Presentation	
	n	%	n	%
Austria	73	3.2%	17	23.3%
Croatia	686	29.6%	102	14.9%
France	546	23.6%	141	25.8%
Ireland	180	7.8%	85	47.2%
Italy	360	15.6%	84	23.3%
Netherlands	258	11.1%	34	13.2%
Portugal	126	5.4%	45	35.7%
United Kingdom	86	3.7%	26	30.2%
Total	2315	100%	534	23.1%

Patient Demographics

		Emergency Presentation?		
		Yes	No	p-value
Age	Mean (SD)	68.1 (11.9)	66.2 (10.2)	<0.001
Sex	Male: n (%)	372 (69.7%)	1214 (68.2%)	0.56
	Female: n (%)	162 (30.3%)	566 (31.8%)	
Performance Status*	0 or 1: n (%)	299 (59.2%)	1347 (81.0%)	<0.001
	2+: n(%)	206 (40.8%)	317 (19.1%)	


^{*}Data available in 2169 patients

Histology & Stage










Principal Presenting Symptom



Treatment

		Emergency Presentation?		n voluo
		Yes	No	p-value
Anti-Cancer Treatment	Yes	382 (82.0%)	1575(93.9%)	∠0.001
	No	84 (18.0%)	103 (6.1%)	<0.001

(n=2144 with complete data)

Management Intent	Curative	55 (13.0%)	457 (39.2%)	<0.001
	Palliative	368 (87.0%)	710 (60.8%)	\0.001

(n=1590 with complete data)



Conclusions

- Consistent patient characteristics
- Expected symptoms and risk-factors
- Advanced disease & palliative treatment more likely
- EP is an issue across Europe
- Significant variation between countries
- EP rates perhaps reflect access to primary care and quality of 1°/2° interaction

Acknowledgements

Rosanna Beradi, Università Politecnica Marche, Ancona, Italy

Gareth Giblin, Norah Cassidy & Linda Coate
All Ireland Co-operative Oncology Research Group, Dublin, Ireland

Ana Figueiredo Porto, Portugal

Gabriele Gamerith

Medizinische Universität Innsbruck, Austria

Marko Jakopović University Hospital Centre Zagreb, Croatia

Cor van der Leest Amphia Hospital, Breda, Netherlands

Damien Pouessel Hopital Saint-Louis, Paris, France

Marcello Tiseo University Hospital of Parma, Italy

Anne-Claire Toffart Centre Hospitalier Universitaire de Grenoble, France.

Cathy Hughes Chelsea & Westminster Hospital, London



Ella Ohuma Nick Ormiston-Smith